TFPI2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P00429(HP Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P00429(HP Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

**Background of TFPI2 Antibody**

Tissue factor pathway inhibitor 2 (TFPI2), a member of the Kunitz-type serine protease inhibitor family, plays a critical role in regulating extracellular matrix (ECM) remodeling, coagulation, and fibrinolysis. It inhibits plasmin-mediated proteolysis by binding to proteases such as plasmin, trypsin, and factor XIa, thereby modulating tissue homeostasis. TFPI2 is expressed in various tissues, including the placenta, liver, and vascular endothelium, and is implicated in pathological conditions like cancer, cardiovascular diseases, and fibrosis.

TFPI2 antibodies are immunochemical tools designed to detect and quantify TFPI2 protein in biological samples. These antibodies are widely used in research to investigate TFPI2’s functional roles, particularly in cancer progression, where its downregulation is associated with tumor invasion and metastasis. In diagnostic contexts, TFPI2 antibodies may aid in identifying diseases linked to ECM dysregulation or abnormal coagulation.

Antibody validation methods, such as Western blotting, immunohistochemistry, and ELISA, ensure specificity and sensitivity. Recent studies highlight TFPI2’s potential as a therapeutic target or biomarker, driving demand for reliable antibodies. Challenges include optimizing cross-reactivity across species and minimizing nonspecific binding. Overall, TFPI2 antibodies are pivotal in advancing our understanding of ECM biology and disease mechanisms.